Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
November 2015

Recent Stories

From Specialty Pharmacy News - When the U.S. Court of Appeals for the Federal Circuit issued a ruling July 21 in the ongoing dispute between Amgen Inc. and Sandoz Inc. over Sandoz’s biosimilar Zarxio (filgrastim-sndz), it seemed to raise more questions than it answered. So it came as a bit of a surprise when the court denied both companies’ requests for rehearing en banc on Oct. 16, setting the stage for a potential U.S. Supreme Court review. And on the FDA front, the comment period on the agency’s draft guidance on biosimilar naming closed, but not before the Federal Trade Commission (FTC) expressed its concerns over the proposal, recommending that the FDA consider other approaches. Read more

As payers grapple with coverage of the $14,000+ per-year PCSK9 inhibitors, Harvard… Read more

A recently published study shows that recommended genetic counseling before women underwent… Read more

A decade ago, ophthalmologists had only one anti-vascular endothelial growth factor (VEGF)… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

November 23, 2015
Repatha Will Be Only PCSK9 Inhibitor Offered by CVS/caremark

Amgen scored an exclusive spot on CVS/caremark's commercial formularies for PCSK9 inhibitor Repatha.

November 11, 2015
Express Scripts Terminates Pharmacy Tied to Horizon

Express Scripts removed a pharmacy with ties to Horizon Pharma from its network.

November 9, 2015
Harvard Pilgrim, Amgen Agree to Pay-for-Value Deal

Harvard Pilgrim just struck a pay-for-performance deal with Amgen for its new PCSK9 inhibitor Repatha.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?